» Articles » PMID: 27100275

Random Non-fasting C-peptide: Bringing Robust Assessment of Endogenous Insulin Secretion to the Clinic

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2016 Apr 22
PMID 27100275
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Measuring endogenous insulin secretion using C-peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non-fasting C-peptide assessment would allow testing when a patient is seen in clinic.

Methods: We compared C-peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated diabetes [median age 72 (interquartile range 68-78); diabetes duration 21 (14-31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose.

Results: rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98.

Conclusions: Random non-fasting C-peptide measures are strongly correlated with mixed meal C-peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C-peptide at the point patients are seen for clinical care.

Citing Articles

Exploring the potential role of C-peptide in type 2 diabetes management.

Lin Y, McCrimmon R, Pearson E Diabet Med. 2025; 42(3):e15469.

PMID: 39797595 PMC: 11823364. DOI: 10.1111/dme.15469.


The epidemiology of type 1 diabetes mellitus in older adults.

Tomic D, Harding J, Jenkins A, Shaw J, Magliano D Nat Rev Endocrinol. 2024; 21(2):92-104.

PMID: 39448829 DOI: 10.1038/s41574-024-01046-z.


Clinical features, biomarkers and diabetic ketoacidosis at diagnosis of type 1 diabetes among children and adolescents in Sana'a, Yemen.

Gunaid A, Ogle G, Al-Qadasi F, Al-Radaei A, Maniam J, El-Shoubaki H BMJ Paediatr Open. 2024; 8(1).

PMID: 39097331 PMC: 11298739. DOI: 10.1136/bmjpo-2024-002680.


Diabetes Study of Children of Diverse Ethnicity and Race: Study design.

Redondo M, Harrall K, Glueck D, Tosur M, Uysal S, Muir A Diabetes Metab Res Rev. 2023; 40(3):e3744.

PMID: 37888801 PMC: 10939959. DOI: 10.1002/dmrr.3744.


Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations.

Builes-Montano C, Wandurraga E, Ramirez A, Ordonez J Diabetes Ther. 2023; 14(11):1959-1976.

PMID: 37736786 PMC: 10570232. DOI: 10.1007/s13300-023-01471-9.


References
1.
Jones A, Hattersley A . The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013; 30(7):803-17. PMC: 3748788. DOI: 10.1111/dme.12159. View

2.
Thanabalasingham G, Pal A, Selwood M, Dudley C, Fisher K, Bingley P . Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care. 2012; 35(6):1206-12. PMC: 3357216. DOI: 10.2337/dc11-1243. View

3.
Besser R, Shields B, Casas R, Hattersley A, Ludvigsson J . Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care. 2012; 36(2):195-201. PMC: 3554273. DOI: 10.2337/dc12-0836. View

4.
Bowman P, McDonald T, Shields B, Knight B, Hattersley A . Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med. 2011; 29(1):90-3. DOI: 10.1111/j.1464-5491.2011.03428.x. View

5.
McDonald T, Perry M, Peake R, Pullan N, OConnor J, Shields B . EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature. PLoS One. 2012; 7(7):e42084. PMC: 3408407. DOI: 10.1371/journal.pone.0042084. View